Chronic idiopathic thrombocytopenic purpura

**Chronic idiopathic thrombocytopenic purpura** (also termed primary immune thrombocytopenia lasting more than 12 months) is an acquired autoimmune hematologic disorder characterized by persistent, isolated thrombocytopenia without a clinically evident secondary cause Clinically, affected individuals may remain asymptomatic or exhibit mucocutaneous bleeding manifestations, including petechiae, purpura, epistaxis, and a heightened risk for severe hemorrhage

**Chronic idiopathic thrombocytopenic purpura** (also termed primary immune thrombocytopenia lasting more than 12 months) is an acquired autoimmune hematologic disorder characterized by persistent, isolated thrombocytopenia without a clinically evident secondary cause

It predominantly affects adults, particularly women of childbearing age, though it can occur in individuals of any age

It predominantly affects adults, particularly women of childbearing age, though it can occur in individuals of any age Pathophysiologically, autoantibodies target platelet surface glycoproteins, driving premature platelet clearance by reticuloendothelial macrophages—predominantly within the spleen—alongside impaired megakaryocyte maturation and reduced thrombopoiesis

It predominantly affects adults, particularly women of childbearing age, though it can occur in individuals of any age Clinically, affected individuals may remain asymptomatic or exhibit mucocutaneous bleeding manifestations, including petechiae, purpura, epistaxis, and a heightened risk for severe hemorrhage

Pathophysiologically, autoantibodies target platelet surface glycoproteins, driving premature platelet clearance by reticuloendothelial macrophages—predominantly within the spleen—alongside impaired megakaryocyte maturation and reduced thrombopoiesis

Pathophysiologically, autoantibodies target platelet surface glycoproteins, driving premature platelet clearance by reticuloendothelial macrophages—predominantly within the spleen—alongside impaired megakaryocyte maturation and reduced thrombopoiesis

Clinically, affected individuals may remain asymptomatic or exhibit mucocutaneous bleeding manifestations, including petechiae, purpura, epistaxis, and a heightened risk for severe hemorrhage